202
Participants
Start Date
January 25, 2022
Primary Completion Date
October 31, 2027
Study Completion Date
October 31, 2027
STK-012
pegylated alpha/beta-biased engineered interleukin-2
pembrolizumab
anti-PD-1 humanized monoclonal antibody
pemetrexed
antifolate chemotherapy
carboplatin
platinum chemotherapy
RECRUITING
NYU Langone Health, New York
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
RECRUITING
Northwell Health, Lake Success
ACTIVE_NOT_RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Georgetown University, Washington D.C.
RECRUITING
NEXT Virginia, Fairfax
RECRUITING
Duke Cancer Center, Durham
RECRUITING
Winship Cancer Institute, Emory University, Atlanta
RECRUITING
Sarah Cannon Research Institute - Nashville, Nashville
RECRUITING
Baptist Memorial Hospital Cancer Center, Memphis
RECRUITING
The James Cancer Hospital and Solove Research Institute, Columbus
RECRUITING
HealthPartners Cancer Center at Regions Hospital, Saint Paul
RECRUITING
Oncology Consultants, Houston
RECRUITING
Renovatio Clinical, The Woodlands
RECRUITING
Renovatio Clinical, El Paso
RECRUITING
University of Arizona Cancer Center, Tucson
RECRUITING
Beverly Hills Cancer Center, Beverly Hills
RECRUITING
UCLA Hematology/Oncology - Santa Monica, Santa Monica
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
RECRUITING
Providence Medical Foundation, Fullerton
RECRUITING
Northwest Medical Specialties, Tacoma
ACTIVE_NOT_RECRUITING
UC San Diego Moores Cancer Center, La Jolla
RECRUITING
Yale New Haven Hospital, Yale Cancer Center, New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Synthekine
INDUSTRY